Merck & Co., Inc. (LON:0QAH)

Market Cap	224.91B +24.1%
Revenue (ttm)	48.30B +1.3%
Net Income	13.56B +6.6%
EPS	5.41 +8.0%
Shares Out	n/a
PE Ratio	16.58
Forward PE	23.82
Dividend	2.45 (2.02%)
Ex-Dividend Date	Dec 15, 2025

Volume	18,041
Average Volume	20,627
Open	121.68
Previous Close	122.18
Day's Range	120.64 - 123.00
52-Week Range	70.15 - 123.71
Beta	0.30
RSI	66.81
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAH

Financial Performance

In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.

Financial numbers in USD